PlumX Metrics
Embed PlumX Metrics

Potential applications for biguanides in oncology

Journal of Clinical Investigation, ISSN: 0021-9738, Vol: 123, Issue: 9, Page: 3693-3700
2013
  • 170
    Citations
  • 0
    Usage
  • 110
    Captures
  • 1
    Mentions
  • 2
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    170
  • Captures
    110
  • Mentions
    1
    • News Mentions
      1
      • News
        1
  • Social Media
    2
    • Shares, Likes & Comments
      2
      • Facebook
        2

Most Recent News

Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome; PRIME

STUDY INFORMATION OFFICIAL TITLE: A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The

Review Description

Metformin is widely prescribed for the treatment of type II diabetes. Recently, it has been proposed that this compound or related biguanides may have antineoplastic activity. Biguanides may exploit specific metabolic vulnerabilities of transformed cells by acting on them directly, or may act by indirect mechanisms that involve alterations of the host environment. Preclinical data suggest that drug exposure levels are a key determinant of proposed direct actions. With respect to indirect mechanisms, it will be important to determine whether recently demonstrated metformin-induced changes in levels of candidate systemic mediators such as insulin or inflammatory cytokines are of sufficient magnitude to achieve therapeutic benefit. Results of the first generation of clinical trials now in progress are eagerly anticipated. Ongoing investigations may justify a second generation of trials that explore pharmacokinetic optimization, rational drug combinations, synthetic lethality strategies, novel biguanides, and the use of predictive biomarkers.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know